To the full analysis
iRhythm Technologies stock: growth
IRTCiRhythm Technologies reported $747.14M in revenue for fiscal 2025, up 26.2% on the prior year, up 23% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
38.2%
per year from 2013 to 2025, per share 5.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 23.0% | 35.4% | 38.2% |
| Revenue per share | 19.6% | 25.3% | 5.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $15.37M | −$13.59M | −$12.3M |
| 2014 | $21.75M | −$15.83M | −$16.17M |
| 2015 | $36.14M | −$22.8M | −$19.79M |
| 2016 | $64.07M | −$20.9M | −$19.41M |
| 2017 | $99.13M | −$29.74M | −$18.47M |
| 2018 | $147.28M | −$50.38M | −$34.25M |
| 2019 | $214.55M | −$54.57M | −$42.32M |
| 2020 | $265.17M | −$43.83M | −$27.31M |
| 2021 | $322.83M | −$101.36M | −$65.82M |
| 2022 | $410.92M | −$116.16M | −$52.84M |
| 2023 | $492.68M | −$123.41M | −$90.53M |
| 2024 | $591.84M | −$113.29M | −$45.55M |
| 2025 | $747.14M | −$44.55M | $34.52M |
Revenue by segment
How iRhythm Technologies, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Commercial Payors52%
- Centers For Medicare And Medicaid24%
- Healthcare Institutions17%
- Non-contracted Third-party Payors7%
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| Commercial Payors | $135.94M | $193.87M | $223.98M | $267.2M | $311.61M | $392.23M | 52.5% |
| Centers For Medicare And Medicaid | $72.54M | $44.53M | $103.03M | $122.41M | $142.39M | $179.35M | 24% |
| Healthcare Institutions | $41.4M | $57.5M | $59.77M | $71M | $95.12M | $125.61M | 16.8% |
| Non-contracted Third-party Payors | $15.3M | $26.93M | $24.13M | $32.07M | $42.73M | $49.94M | 6.7% |
| Total revenue | $265.17M | $322.83M | $410.92M | $492.68M | $591.84M | $747.14M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.